Publication | Open Access

Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer

Breast OncologyMedicineAnti-frizzled Antibody VantictumabImmunologyPathologyBreast CancerCancer TreatmentOncologyRadiation Oncology